PMID- 30909821
OWN - NLM
STAT- MEDLINE
DCOM- 20200522
LR  - 20200522
IS  - 2159-9777 (Electronic)
IS  - 0279-1072 (Linking)
VI  - 51
IP  - 2
DP  - 2019 Apr-Jun
TI  - Embracing Neurodiversity in Psychedelic Science: A Mixed-Methods Inquiry into the 
      MDMA Experiences of Autistic Adults.
PG  - 146-154
LID - 10.1080/02791072.2019.1587116 [doi]
AB  - This exploratory inquiry analyzed subjective experiences autistic adults reported 
      after they took the drug 3,4-methylenedioxymethamphetamine (MDMA), also known as 
      ecstasy, in nonclinical settings. Using a secure, globally available website, 
      this study collected data from participants in 13 countries who were experienced 
      with MDMA (n = 100). A subset of survey respondents (n = 24) were then invited to 
      participate in qualitative interviews. The researcher applied thematic content 
      analysis of interview transcripts to create a comprehensive account of emergent 
      themes. MDMA has well-documented acute effects that promote pro-social attitudes 
      such as caring and trust in neurotypical, or typically developing, populations. 
      Findings from this study suggested that MDMA-assisted therapy may be an effective 
      catalyst in autistic adults for intra- and interpersonal change. In addition, 
      participants reported accounts of lasting transformation and healing from 
      conditions such as trauma and social anxiety that are common in autistic 
      populations. No participants reported long-term adverse outcomes as a result of 
      using MDMA/ecstasy. Qualitative findings support a case for future clinical 
      trials of MDMA-assisted therapy with autistic adults who present with social 
      adaptability challenges.
FAU - Danforth, Alicia L
AU  - Danforth AL
AD  - a Los Angeles Biomedical Research Institute, Harbor-UCLA Medical Center , 
      Torrance , CA , USA.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20190325
PL  - United States
TA  - J Psychoactive Drugs
JT  - Journal of psychoactive drugs
JID - 8113536
RN  - 0 (Hallucinogens)
RN  - KE1SEN21RM (N-Methyl-3,4-methylenedioxyamphetamine)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Autistic Disorder/*drug therapy/psychology
MH  - Female
MH  - Hallucinogens/*administration & dosage/adverse effects/pharmacology
MH  - Humans
MH  - Interviews as Topic
MH  - Male
MH  - Middle Aged
MH  - N-Methyl-3,4-methylenedioxyamphetamine/*administration & dosage/adverse 
      effects/pharmacology
MH  - Phobia, Social/psychology
MH  - Surveys and Questionnaires
MH  - Young Adult
OTO - NOTNLM
OT  - Asperger's
OT  - MDMA
OT  - autism
OT  - social anxiety
EDAT- 2019/03/27 06:00
MHDA- 2020/05/23 06:00
CRDT- 2019/03/27 06:00
PHST- 2019/03/27 06:00 [pubmed]
PHST- 2020/05/23 06:00 [medline]
PHST- 2019/03/27 06:00 [entrez]
AID - 10.1080/02791072.2019.1587116 [doi]
PST - ppublish
SO  - J Psychoactive Drugs. 2019 Apr-Jun;51(2):146-154. doi: 
      10.1080/02791072.2019.1587116. Epub 2019 Mar 25.